Future Outlook and Clinical Integration of HER2-Targeted Strategies in NSCLC

Drs. Santos and Lopes provide a forward-looking perspective on the future of HER2-targeted therapy in NSCLC, emphasizing ongoing clinical trials and anticipated paradigm shifts. They discuss the potential for earlier-line use of ADCs, as well as combination strategies that may further improve outcomes.

The faculty highlight the importance of continued research to refine patient selection, optimize sequencing, and enhance safety profiles. They also note the role of emerging biomarkers in predicting response and guiding therapy.

The discussion reinforces the need for oncologists to stay current with rapidly evolving data, as HER2-targeted therapy is poised to become an increasingly integral component of NSCLC management. Integration into clinical practice will depend on guideline updates, access, and clinician familiarity with these agents.

The program concludes with a clear message: HER2-mutated NSCLC is transitioning from a niche subset with limited options to a highly actionable disease state with expanding therapeutic opportunities, requiring ongoing education and adaptation by practicing oncologists.